346 related articles for article (PubMed ID: 29315147)
1. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature.
Hagen JW; Pugliano-Mauro MA
Dermatol Surg; 2018 Apr; 44(4):469-480. PubMed ID: 29315147
[TBL] [Abstract][Full Text] [Related]
2. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.
Bahi M; Walmsley RS; Gray AR; Young D; Hobbs CE; Aluzaite K; Schultz M
J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142
[TBL] [Abstract][Full Text] [Related]
3. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.
Ariyaratnam J; Subramanian V
Am J Gastroenterol; 2014 Feb; 109(2):163-9. PubMed ID: 24419479
[TBL] [Abstract][Full Text] [Related]
4. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis.
Huang SZ; Liu ZC; Liao WX; Wei JX; Huang XW; Yang C; Xia YH; Li L; Ye C; Dai SX
J Gastroenterol Hepatol; 2019 Mar; 34(3):507-516. PubMed ID: 30393891
[TBL] [Abstract][Full Text] [Related]
5. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
[TBL] [Abstract][Full Text] [Related]
6. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
[TBL] [Abstract][Full Text] [Related]
7. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
8. Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis.
Narous M; Nugent Z; Singh H; Bernstein CN
Inflamm Bowel Dis; 2023 Jul; 29(7):1047-1056. PubMed ID: 35929649
[TBL] [Abstract][Full Text] [Related]
9. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
10. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.
Long MD; Herfarth HH; Pipkin CA; Porter CQ; Sandler RS; Kappelman MD
Clin Gastroenterol Hepatol; 2010 Mar; 8(3):268-74. PubMed ID: 20005977
[TBL] [Abstract][Full Text] [Related]
11. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
Amin J; Huang B; Yoon J; Shih DQ
Inflamm Bowel Dis; 2015 Feb; 21(2):445-52. PubMed ID: 25248004
[TBL] [Abstract][Full Text] [Related]
12. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts.
Jharap B; Seinen ML; de Boer NK; van Ginkel JR; Linskens RK; Kneppelhout JC; Mulder CJ; van Bodegraven AA
Inflamm Bowel Dis; 2010 Sep; 16(9):1541-9. PubMed ID: 20155846
[TBL] [Abstract][Full Text] [Related]
13. Thiopurine use associated with reduced B and natural killer cells in inflammatory bowel disease.
Lord JD; Shows DM
World J Gastroenterol; 2017 May; 23(18):3240-3251. PubMed ID: 28566883
[TBL] [Abstract][Full Text] [Related]
14. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines.
Dotan I; Werner L; Vigodman S; Agarwal S; Pfeffer J; Horowitz N; Malter L; Abreu M; Ullman T; Guzner-Gur H; Halpern Z; Mayer L
Inflamm Bowel Dis; 2012 Feb; 18(2):261-8. PubMed ID: 21438101
[TBL] [Abstract][Full Text] [Related]
15. Optimizing thiopurine therapy in inflammatory bowel disease.
Chevaux JB; Peyrin-Biroulet L; Sparrow MP
Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
[TBL] [Abstract][Full Text] [Related]
16. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
[TBL] [Abstract][Full Text] [Related]
17. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis.
Jess T; Lopez A; Andersson M; Beaugerie L; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1793-1800.e1. PubMed ID: 24907505
[TBL] [Abstract][Full Text] [Related]
18. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study.
Setshedi M; Epstein D; Winter TA; Myer L; Watermeyer G; Hift R
J Gastroenterol Hepatol; 2012 Feb; 27(2):385-9. PubMed ID: 21793904
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
[TBL] [Abstract][Full Text] [Related]
20. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.
Abbas AM; Almukhtar RM; Loftus EV; Lichtenstein GR; Khan N
Am J Gastroenterol; 2014 Nov; 109(11):1781-93. PubMed ID: 25244964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
